Use of Mepolizumab in Children and Adolescents with Asthma in the USA
Authors:
- Jaclyn DavisJDJaclyn Davis
- Pamela M. McMahonPMPamela M. McMahon
- Emily WelchEWEmily Welch
- Cheryl McMahill-WalravenCMCheryl McMahill-Walraven
- Aziza Jamal-AllialAziza Jamal-Allial
- Tancy ZhangTZTancy Zhang
- Christine DraperCDChristine Draper
- Anne Marie KlineAKAnne Marie Kline
- Leslie KoernerLKLeslie Koerner
- Jeffrey S. BrownJBJeffrey S. Brown
- Melissa Van DykeMDMelissa Van Dyke
- Ann Chen WuAnn Chen Wu
Open Access
- 19 July 2022
- journal article
- research article
- Published by MDPI AG in Journal of Respiration
- Vol. 2 (3) , 123-128
Abstract
Introduction: Pediatric asthma affects 5.5 million US children and is the leading cause of pediatric chronic illness globally. Those with severe asthma have significantly higher healthcare costs compared to those with non-severe disease. Biologics are the newest class of anti-asthma therapy approved for use in patients with severe asthma > 6 years with the eosinophilic phenotype. Objective: The goals of this study were to (1) describe the baseline characteristics of new US pediatric mepolizumab users between 2015 and end dates that varied by data partner (6/30/19–5/31/21), (2) describe asthma medication use in the 12 months preceding and following mepolizumab initiation in this group and (3) assess adherence and persistence to mepolizumab in the 12 months following initiation. Methods: Through an observational cohort study using insurance claim databases, we studied children with a diagnosis of asthma in the preceding 12 months who started mepolizumab and had 12 months of follow-up data. Results: Baseline characteristics of the 72 children who initiated mepolizumab showed variable comorbidities, the most common being allergic rhinitis (88%) and recurrent respiratory infections (71%), as well as varied medication dispensings and patterns of healthcare utilization prior to initiating mepolizumab. Half met the criteria for severe asthma per the GINA guidelines. Comparing weighted averages of treatments dispensed in the 12 months prior to versus following mepolizumab initiation, we observed no significant change in asthma treatments dispensed. Conclusion: This study demonstrates that pediatric patients prescribed mepolizumab have variable previous treatment history and severity of disease, and we found no evidence that mepolizumab alters other asthma medications dispensed in the first 12 months following initiation.Keywords
Funding Information
- GSK (PRJ2757)
This publication has 13 references indexed in Scilit:
- Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthmaPediatric Pulmonology, 2019
- Rhinitis in children and adolescents with asthma: Ubiquitous, difficult to control, and associated with asthma outcomesJournal of Allergy and Clinical Immunology, 2019
- The FDA Sentinel Initiative — An Evolving National ResourceNew England Journal of Medicine, 2018
- Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trialThe Lancet Respiratory Medicine, 2017
- Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapyAnnals of Allergy, Asthma & Immunology, 2015
- Global burden of asthma among childrenThe International Journal of Tuberculosis and Lung Disease, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012
- Economic burden of impairment in children with severe or difficult-to-treat asthmaAnnals of Allergy, Asthma & Immunology, 2011
- Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma–Summary Report 2007Journal of Allergy and Clinical Immunology, 2007